Choosing a Cas9 Variant and Delivery Format for Your Cell Type

The nuclease and the delivery method are usually discussed as separate choices. In practice they are coupled: the payload size constrains the vector, the vector constrains the cell type, and the cell type constrains the acceptable toxicity.

The efficient order of decisions is therefore:

1. What edit do you need? (determines PAM and nick requirements)
2. What cell type must survive it? (determines acceptable delivery and toxicity)
3. What cargo size does the vector allow? (determines which nuclease fits)
4. What validation can you afford? (determines whether a high-fidelity variant is worth its efficiency cost)

The fidelity variants deserve a specific note: they are not strictly better. They trade activity for specificity, and in hard-to-edit cells that trade can make an experiment infeasible. Use them when off-target risk is the binding concern, not by default.

Two rules of thumb that hold across most systems: shorter exposure reduces off-target editing, which is why RNP and mRNA are preferred for therapeutic-grade work; and stable expression is what you want for interference and activation, where sustained dCas9 is the point.

The post-mitotic point matters for editing strategy, not only delivery: HDR-based knock-in is inefficient without division, so base or prime editing (which do not require a repair template) are often the practical route.

• • Editing efficiency in your actual cell type, not in HEK293. A guide that works at 80% in a transformed line may work at 10% in primary cells.
• • Toxicity and viability at the chosen dose; electroporation and high RNP doses are the usual culprits.
• • Plasmid integration if using plasmids — a real risk that is rarely checked.
• • dCas9 expression level for stable lines: too high causes toxicity and artefactual effects.

Applied to a concrete case — an iPSC line, a knock-in reporter at an endogenous locus — the sequence runs:

1. Edit type: knock-in, so an HDR template is needed; the payload is a fluorescent protein, so prime editing is impractical and plasmid HDR is the realistic route.
2. Cell type: iPSCs tolerate plasmid poorly — random integration and differentiation are common. RNP or mRNA delivery with a single-stranded or plasmid donor is preferred, accepting a lower HDR rate.
3. Vector: no AAV constraint if electroporation is available, so SpCas9 remains an option; if AAV were required, SaCas9 or a compact variant would be forced.
4. Fidelity: iPSCs are expanded clonally and banked, so a fidelity variant is justified if efficiency holds; test both.

The generalization: the delivery format, not the nuclease, is usually the binding constraint — and the nuclease is then chosen to fit what the format can carry.

EDITGENE runs editing in immortalized, iPSC, and primary-like backgrounds with format-appropriate delivery (RNP, mRNA, lentiviral), reports efficiency and toxicity per format, and delivers validated clones or pools.

Tell us the cell type and the edit. Contact EDITGENE to request a project consultation or quote.

Variant performance and delivery efficiency vary by cell type, locus, and protocol; the table entries describe general properties rather than measured efficiencies.

Any delivery format requires validation of on-target editing, toxicity, and — where relevant — integration status in the intended cell type.

• • Ran FA, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520:186–191.
• • Kleinstiver BP, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529:490–495.
• • Zetsche B, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163:759–771.
• • Kim S, et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Research. 2014;24:1012–1019.